14 results about "HPV Antigen" patented technology

The present invention provides an HPV antigen epitope and its application, wherein the use of the first amino acid of the HPV antigen epitope in mediating the binding of the HPV antigen epitope to HLA-A*02:01 is disclosed, wherein the HPV antigen epitope has the amino acid sequence shown in SEQ ID NO:1. The inventors found that a mutation in the first amino acid of the amino acid sequence shown in SEQ ID NO:1 affects the binding activity and immunogenicity of the HPV antigen epitope to HLA-A*02:01. The HPV antigen epitope obtained by mutation of SEQ ID NO:1 has a stronger affinity and immunogenicity than SEQ ID NO:1, and the HPV antigen epitope-loaded T2 cells or tumor cells produce a stronger killing effect. Therefore, drugs and vaccines prepared from the HPV antigen epitope obtained after mutation can effectively treat various cancers, and are safer and have fewer side effects.

The present application provides a T cell receptor (TCR) having the property of binding to YMLDLQPET-HLA A0201 complex; and the binding affinity of the TCR to the YMLDLQPET-HLA A0201 complex is at least 2 times the binding affinity of the wild-type TCR to the YMLDLQPET-HLA A0201 complex. The present application also provides a fusion molecule of such TCR and a therapeutic agent. Such TCR can be used alone or in combination with a therapeutic agent to target tumor cells presenting YMLDLQPET-HLA A0201 complex.

The present application provides modified PBMCs for treating HPV-associated cancers. The modified PBMCs are derived from input PBMCs in which at least one HPV antigen has been delivered intracellularly. In some embodiments, the PBMCs are administered in combination with a checkpoint inhibitor such as a CTLA4 antagonist and / or a PD-1 / PD-L1 agonist.

Safe, rapid, and efficient methods for producing antigen-specific T cells recognizing human papilloma virus (HPV antigens); HPV-specific T cells, and methods for treating HPV infections and HPV-related malignancies by adoptive transfer of HPV-specific T cells.

The invention discloses a therapeutic vaccine for human papilloma virus infection and a preparation method thereof. In particular to a composition for preventing and / or treating diseases caused by HPV infection. The composition comprises DC cells loaded with HPV antigens and exosomes. The invention also discloses a preparation method of the composition. The therapeutic vaccine provided by the invention comprises a SiHa cell exosome, an MS751 cell exosome and a human DC cell loaded with HPV VLPs (L1 protein virus-like particles of HPV). Experiments show that the therapeutic vaccine can induce and significantly enhance HPV specific CTL immune response, has an obvious killing effect on cervical cancer cells, can enhance anti-tumor immune response, and enhances the immunity of an organism to diseases, thereby achieving a therapeutic effect. The therapeutic vaccine can effectively treat HPV infection and diseases caused by the HPV infection, or prevent deterioration of the HPV infection and the diseases caused by the HPV infection.

Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and / or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and / or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.

The present application provides enhanced APCs for treating HPV-associated cancers. The enhanced APCs are capable of activating T cells in an HLA agnostic manner and are derived from input APCs in which at least one nucleic acid encoding an HPV antigen has been delivered intracellularly. In some aspects, the enhanced APCs are administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1 / PD-L1 and / or an antagonist of CTLA-4.

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and / or for modulating an immune response in an individual with an HPV-associated disease.

Provided are an HPV vaccine containing a nucleic acid molecule encoding an HPV antigen and an immune costimulatory factor, and the use thereof.

The invention discloses a therapeutic vaccine for human papilloma virus infection and a preparation method thereof. In particular to a composition for preventing and / or treating diseases caused by HPV infection. The composition comprises DC cells loaded with HPV antigens and exosomes. The invention also discloses a preparation method of the composition. The therapeutic vaccine provided by the invention comprises a SiHa cell exosome, an MS751 cell exosome and a human DC cell loaded with HPV VLPs (L1 protein virus-like particles of HPV). Experiments show that the therapeutic vaccine can induce and significantly enhance HPV specific CTL immune response, has an obvious killing effect on cervical cancer cells, can enhance anti-tumor immune response, and enhances the immunity of an organism to diseases, thereby achieving a therapeutic effect. The therapeutic vaccine can effectively treat HPV infection and diseases caused by the HPV infection, or prevent deterioration of the HPV infection and the diseases caused by the HPV infection.

The invention discloses a fermentation method of a high-yield HPV antigen bacterium and a method for producing an HPV antigen, and relates to the technical field of HPV antigen expression. According to the method, a fermentation culture medium is screened and optimized, dissolved oxygen associated feeding is carried out in the fermentation process to control consumption of nutrient materials of strains, and better fermentation and protein induction conditions are screened out, so that synthesis of a large amount of target protein is promoted, synthesis expression of host protein is inhibited, and finally, the yield of HPV antigens is remarkably increased; and the ratio of the yield of the target protein to the total protein is greatly increased. And the problem that the expression quantity is difficult to increase is thoroughly solved.

The present application provides immune cells comprising an HPV antigen and an adjuvant, methods of manufacturing such modified immune cells, and methods of using such modified immune cells for treating an HPV-associated disease, preventing an HPV-associated disease and / or for modulating an immune response in an individual with an HPV-associated disease.